Pfizer

News

PARP rivals close in on AZ and Merck's market leading Lynpar...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market s

News

A sweet little mixed race boy sits up on an examination table as he receives an immunization. He is looking up and smiling as the doctor places the bandage on his arm. Both are wearing medical masks to protect them from COVID.

Pfizer/BioNTech ask FDA for EUA of Omicron bivalent vaccine ...

A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for

News

Pfizer, Sangamo resume haemophilia gene therapy trial

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene fitelparvovec, after the FDA lifted a clinical hold on t

News

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

News

Data-crunching specialist CytoReason signs $110m Pfizer alli...

Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship into a lucrative, wide-ranging contract

News

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.<

PARP rivals close in on AZ and Merck's market leading Lynpar...

Pfizer/BioNTech ask FDA for EUA of Omicron bivalent vaccine ...

Pfizer, Sangamo resume haemophilia gene therapy trial

Routine NHS access to Ibrance assured with new NICE guidance

Data-crunching specialist CytoReason signs $110m Pfizer alli...

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks